Mmastodon WorldWorld first seen 14 h ago, last 14 h ago, peak #1
Twice-yearly HIV prevention injection hailed, access questioned
Original: HIV prevention drug hailed as breakthrough, but who gets access? https://www. aljazeera.com/news/2026/10/1/h iv-preventi
Lenacapavir, a twice-a-year injection for HIV prevention, is being hailed as a breakthrough that could sharply reduce new infections. But attention is turning to whether the drug will reach the people who need it most, with cost and availability in lower-income countries emerging as key concerns among health advocates and commentators.
Why now: The drug's approval and potential to transform HIV prevention have sparked debate over equitable global access.
LenacapavirAl JazeeraWorld Health OrganizationGilead Sciences
Evidence
- HIV prevention drug hailed as breakthrough, but who gets access? https://www. aljazeera.com/news/2026/10/1/h iv-prevention-drug-hailed-as-breakthrough-but-who-gets-access?traffic_source=rss Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be… · MillMessenger@journa.host · 3
API: https://socialmediatrends-api.osmike.com/v1/trends/625189